Neurocrine sells Ingrezza for movement disorders.
Neurocrine Biosciences, Inc. (NBIX) is expected to report earnings on Tuesday, October 27, 2026, after the close. Estimated release time 16:02 ET. Consensus EPS estimate is $2.59.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | FY2026 Q2 | $1.65 | $1.39 | -15.8% | $959.00M |
| 2026-05-05 | FY2026 Q1 | $1.22 | $1.94 | +59.0% | $814.50M |
| 2026-02-11 | FY2025 Q4 | $1.80 | $1.88 | +4.4% | $805.50M |
| 2025-10-28 | FY2025 Q3 | $1.58 | $2.04 | +29.1% | $794.90M |
| 2025-07-30 | FY2025 Q2 | $0.98 | $1.06 | +8.2% | $687.50M |
| 2025-02-06 | FY2024 Q4 | $1.62 | $1.69 | +4.3% | $627.70M |
| 2024-10-30 | FY2024 Q3 | $1.51 | $1.24 | -17.9% | $622.10M |
| 2024-08-01 | FY2024 Q2 | $1.05 | $0.63 | -40.0% | $590.20M |
NBIX has beaten consensus EPS in 5 of its last 8 reported quarters.
NBIX reported Jul 30. The highlights: EPS of $1.39 — a sharp miss vs the $1.65 estimate (-16%); revenue of $959M — a beat vs the $891M consensus (+8%). Focus now shifts to Ingrezza growth and pipeline readouts.
See NBIX on the live calendar →